journal

Oncology (Williston Park, NY)

journal
https://read.qxmd.com/read/31661154/personality-disorders-in-patients-with-cancer
#1
Daniel C McFarland, Jody Morita, Yesne Alici
Personality disorders exist on a spectrum in the general population and therefore may coexist in patients who have cancer. Patients with these disorders exhibit character rigidity resulting from enduring patterns of inner experience and behavior and may experience some level of interpersonal conflict among medical staff caring for them. These conditions become exacerbated under stressful cancer-related situations and may lead to adverse consequences and outcomes. This review highlights the conceptual and diagnostic issues of personality disorders for practicing oncologists and provides recommendations for recognizing and managing cancer patients with difficult personality traits or personality disorders...
October 28, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31661153/immunotherapy-in-colorectal-cancer
#2
Mehmet Sitki Copur
Colorectal cancer (CRC) is the third leading cause of cancer deaths, with only 15% of patients surviving 5 years in the metastatic setting. Recent exciting developments in cancer immunotherapy, which involves priming the host's natural immune defenses to recognize, target, and destroy cancer cells effectively, have brought some glimpse of hope in fighting this deadly disease. Although CRC has been shown to evade immune detection like many other cancers do, immunotherapy has been noted to produce some very impressive results in a select group of patients...
October 28, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31661152/mutations-and-the-importance-of-genetic-testing
#3
Allison W Kurian
There is some controversy over whether every single woman with breast cancer shold have genetic testing, or whether it should only those who have some personal or family history that would suggest their breast cancer may be linked to an inherited mutation. There are also tests of the tumor that look for somatic mutations. Here, we explore the arguments and options.
October 28, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31661151/classifying-dlbcl-subtypes-for-optimal-treatment
#4
Jennifer Crombie
DLBCL is the most common subtype of non-Hodgkin lymphoma, representing about 30% to 40% of cases. Patients are typically diagnosed with an excisional lymph node biopsy or a biopsy of another affected organ. When pathologists look under the microscope, they can see a diffused proliferation of large neoplastic B cells. These B cells are identified by flow cytometry or immunohistochemistry that identifies pan-B-cell antigens such as CD19, CD20, and CD79a, as well as CD45. DLBCL is known to be an aggressive lymphoma, but it is also known to be both clinically and molecularly heterogeneous...
October 28, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31661150/immunotherapy-advances-2019
#5
Naveed Saleh
The year 2019 has offered up many advances in immunotherapy. These advances shed light on such important aspects as biomarkers, better targeted therapies, chemotherapy outcomes, and resistance. Summarized herein are several high-profile conference presentations that highlight key advances in the field.
October 28, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31661149/metastasis-directed-therapy-in-prostate-cancer-why-when-and-how
#6
Ryan M Phillips, Matthew P Deek, Theodore L Deweese, Phuoc T Tran
Metastatic prostate cancer remains a life-limiting disease; while we have seen significant advances in systemic approaches which form the backbone of management, no curative paradigm yet exists. Metastasis-directed therapy (MDT) with stereotactic ablative radiotherapy (SABR) has emerged as a promising complementary technique for the management of low-volume metastatic prostate cancer. Herein we will review the rationale, potential benefits, and practical considerations associated with this approach.
October 28, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31661148/next-generation-of-lung-cancer-management
#7
Benjamin Levy
The most important lung cancer research falls under the hub of personalized medicine. There is an expanding list of lung cancer genotypes that researchers have identified as relevant, and even more importantly, that they have discovered targeted therapies for. In addition, scientists are learning more about predictive markers for immunotherapy that may inform clinicians on how to optimally treat patients. Both targeted therapy and immunotherapy are approved in advanced non-small cell lung cancer and oncologists are learning more about the utility for these drugs in earlier stage disease...
October 28, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31571185/fda-approved-uses-of-cabozantinib
#8
Jennifer Leavitt, Mehmet Sitki Copur
No abstract text is available yet for this article.
September 20, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31571184/practical-dosing-considerations-for-venetoclax
#9
Kelly Valla
No abstract text is available yet for this article.
September 20, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31571183/therapy-options-for-patients-with-hepatocellular-carcinoma
#10
Crystal Denlinger
No abstract text is available yet for this article.
September 20, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31571182/biliary-cancer-current-multimodality-treatment-and-future-directions
#11
Mehmet Sitki Copur, Shaheed Merani, Luciano M Vargas
Biliary cancer is a highly aggressive malignancy arising from the biliary tree, with its incidence increasing steadily on a global level. Most biliary cancers are diagnosed in the advanced and metastatic stages due to the paucity of signs and symptoms in the early presentation. Only about one-third of the patients can be treated with curative intent with an overall median survival of less than 24 months for all-comers from the time of diagnosis. This fact and the poor results of the currently available local and systemic therapies, are responsible for the disappointing outcome of biliary cancer patients...
September 20, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31571181/drugs-in-the-pipeline-non-small-cell-lung-cancer
#12
Naveed Saleh
No abstract text is available yet for this article.
September 20, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31571180/clinical-trials-in-breast-and-endometrial-cancer
#13
Anna Azvolinsky, Joanna Pangilinan
No abstract text is available yet for this article.
September 20, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31571179/67-year-old-male-with-prostatic-stromal-tumor-of-uncertain-malignant-potential
#14
Luke Bidikov, Paul Maroni, Simon Kim, E David Crawford
No abstract text is available yet for this article.
September 20, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31571178/game-changers-in-treatment-of-hematologic-malignancies
#15
Andre Goy
No abstract text is available yet for this article.
September 20, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31469905/monitoring-for-thyroid-cancer-recurrence
#16
Alan N Peiris
No abstract text is available yet for this article.
August 23, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31469904/current-clinical-trials-in-prostate-cancer
#17
Naveed Saleh
No abstract text is available yet for this article.
August 23, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31469903/gilteritinib-changes-aml-landscape
#18
Naveed Saleh
No abstract text is available yet for this article.
August 23, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31469902/atezolizumab-and-its-many-uses
#19
Naveed Saleh, Mehmet Sitki Copur
No abstract text is available yet for this article.
August 23, 2019: Oncology (Williston Park, NY)
https://read.qxmd.com/read/31469901/universal-genetic-testing-for-all-breast-cancer-patients
#20
Mehmet Sitki Copur
Women with pathogenic BRCA1/2 mutations are more likely to develop breast cancer than are women without the mutation and they typically develop cancer at an earlier age. If women are aware of their BRCA1/2 status, however, they can make timely decisions about preventive measures such as chemoprevention with hormonal agents or undergoing prophylactic surgery, all of which have been shown to reduce the risk of cancer and overall mortality. The US Preventive Services Task Force and the National Comprehensive Cancer Network have recommended that women with a family history of breast, ovarian, and certain other cancers consider BRCA1/2 testing...
August 23, 2019: Oncology (Williston Park, NY)
journal
journal
29689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"